Nasdaq · CIK 0000027367
DXR DAXOR CORP
Insider trading from SEC Form 4. Last filing 42 d ago. Close $10.41 on Oct 9, 2026, +17% from the 52-week low and -29% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
DXROct 9, 2026 · close 10.41
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at DAXOR CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Michael Richard Feldschuh Chief Executive Officer buy | $9,070 1,000 shares | +0% | +26% from low-38% from high | |
| 38Weak | Robert J Michel Chief Financial Officer buy | $9,900 1,000 shares | +5% | +34% from low-34% from high | |
| 39Weak | Michael Richard Feldschuh Chief Executive Officer buy | $16k 2,063 shares | +1% | +8% from low-23% from high | |
| 25Weak | Michael Richard Feldschuh Chief Executive Office buy | $8,130 1,000 shares | +0% | - | |
| 20Weak | Michael Richard Feldschuh Chief Executive Officer buy | $5,273 647 shares | +0% | - | |
| 38Weak | Michael Richard Feldschuh Chief Executive Officer buy | $26k 3,360 shares | +2% | - | |
| 33Weak | Robert J Michel Chief Financial Officer buy | $8,000 1,000 shares | +6% | - |
Transactions
The last 27 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | John Jefferies Chief Medical Officer | AGrant or award Daxor Common Stock | +2,451 | $0.00 | $0 | 26,008 | 42 d ago |
| Jun 23, 2026 | Henry D. Cremisi director | AGrant or award Stock Options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 25, 2026 |
| Jun 23, 2026 | Caleb DesRosiers director | AGrant or award Stock options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 25, 2026 |
| Jun 23, 2026 | Edward Feuer director | AGrant or award Stock Options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 25, 2026 |
| Jun 23, 2026 | Joy S. Goudie director | AGrant or award Stock Options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 25, 2026 |
| Jun 23, 2026 | Jonathan Adam Feldschuh Chief Scientific Officer | AGrant or award Daxor Common Stock | +25,000 | $0.00 | $0 | 78,908 | Jun 25, 2026 |
| Jun 23, 2026 | Michael Richard Feldschuh Chief Executive Officer | AGrant or award Daxor Common Stock | +30,000 | $0.00 | $0 | 243,694 | Jun 25, 2026 |
| Jun 23, 2026 | Robert J Michel Chief Financial Officer | AGrant or award Daxor Common Stock | +12,000 | $0.00 | $0 | 33,050 | Jun 25, 2026 |
| Apr 8, 2026 | Michael Richard Feldschuh Chief Executive Officer | POpen-market purchase Daxor Common Stock | +1,000 | $9.07 | $9,070 | 213,694 | Apr 10, 2026 |
| Mar 31, 2026 | Robert J Michel Chief Financial Officer | POpen-market purchase Daxor Common Stock | +1,000 | $9.90 | $9,900 | 21,050 | Mar 31, 2026 |
| Mar 20, 2026 | John Jefferies Chief Medical Officer | POpen-market purchase Daxor Common Stock | +3,656 | $0.00 | $0 | 21,272 | Mar 24, 2026 |
| Mar 20, 2026 | John Jefferies Chief Medical Officer | POpen-market purchase Daxor Common Stock | +2,285 | $0.00 | $0 | 23,557 | Mar 24, 2026 |
| Dec 9, 2025 | Robert J Michel Chief Financial Officer | POpen-market purchase Daxor Common Stock | +3,000 | $0.00 | $0 | 20,050 | Dec 11, 2025 |
| Dec 9, 2025 | Jonathan Adam Feldschuh Chief Scientific Officer | POpen-market purchase Daxor Common Stock | +18,000 | $0.00 | $0 | 53,908 | Dec 11, 2025 |
| Nov 12, 2025 | John Jefferies Chief Medical Officer | POpen-market purchase Daxor Common Stock | +2,344 | $0.00 | $0 | 17,616 | Nov 14, 2025 |
| Jun 24, 2025 | Henry D. Cremisi director | AGrant or award Stock Options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 26, 2025 |
| Jun 24, 2025 | Caleb DesRosiers director | AGrant or award Stock options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 26, 2025 |
| Jun 24, 2025 | Edward Feuer director | AGrant or award Stock Options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 26, 2025 |
| Jun 24, 2025 | Joy S. Goudie director | AGrant or award Stock Options (right to buy)derivative | +2,500 | $0.00 | $0 | 2,500 | Jun 26, 2025 |
| Apr 4, 2025 | Michael Richard Feldschuh Chief Executive Officer | POpen-market purchase Daxor Common Stock | +2,063 | $7.89 | $16k | 212,694 | Apr 7, 2025 |
| Mar 26, 2024 | Michael Richard Feldschuh Chief Executive Office | POpen-market purchase Daxor Common Stock | +1,000 | $8.13 | $8,130 | 210,631 | Mar 27, 2025 |
| Mar 19, 2024 | Michael Richard Feldschuh Chief Executive Officer | POpen-market purchase Daxor Common Stock | +647 | $8.15 | $5,273 | 209,631 | Mar 20, 2025 |
| Mar 10, 2025 | Michael Richard Feldschuh Chief Executive Officer | POpen-market purchase Daxor Common Stock | +3,360 | $7.68 | $26k | 210,852 | Mar 11, 2025 |
| Mar 10, 2025 | Robert J Michel Chief Financial Officer | POpen-market purchase Daxor Common Stock | +1,000 | $8.00 | $8,000 | 17,050 | Mar 11, 2025 |
| Dec 6, 2024 | Michael Richard Feldschuh Chief Executive Officer | POpen-market purchase Daxor Common Stock | +45,000 | $0.00 | $0 | 207,492 | Dec 10, 2024 |
| Dec 6, 2024 | Jonathan Adam Feldschuh Chief Scientific Officer | POpen-market purchase Daxor Common Stock | +32,000 | $0.00 | $0 | 35,908 | Dec 10, 2024 |
| Mar 27, 2023 | Robert J Michel Chief Financial Officer | POpen-market purchase Daxor Common Stock | +4,750 | $0.00 | $0 | 15,050 | Dec 10, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Henry D. Cremisidirector
- Caleb DesRosiersdirector
- Jonathan Adam FeldschuhChief Scientific Officer
- Michael Richard FeldschuhChief Executive Officer
- Edward Feuerdirector
- Joy S. Goudiedirector
- John JefferiesChief Medical Officer
- Robert J MichelChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.